GlobeNewswire by notified

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

Share
  • Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million
  • The sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss moratorium proceedings
  • Sale proceeds expected to position ObsEva to satisfy Nasdaq stockholders’ equity requirement for continued public listing
  • ObsEva expects to have greater than one year of cash runway, providing strategic optionality


Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, Switzerland – November 22, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (“ObsEva” or the “Company”), a biopharmaceutical company developing novel therapies for women’s health, today announced the sale of all of the Company’s rights to Ebopiprant to XOMA Corporation (XOMA) for an upfront payment of $15 million and future milestone payments of up to $98 million. ObsEva expects the sale proceeds to resolve its current over-indebtedness position, enabling the Company to withdraw the Company’s previously announced moratorium proceedings before Swiss courts, as well as position the Company to regain compliance with minimum stockholders’ equity requirements for continued listing on The Nasdaq Stock Market (“Nasdaq”).

“The sale of the Ebopiprant license agreement both strengthens our immediate financial position, while providing the potential for future upside for shareholders,” said Brian O’Callaghan, CEO of ObsEva. “The transaction marks the successful completion of a restructuring process whereby we have extracted material savings through the assignment of contracts, streamlined our organizational structure, and restructured our debt. With the receipt of the upfront payment, we expect to have more than a year of cash runway and an enhanced strategic position, and we intend to turn the Company’s resources towards nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization, while also evaluating strategic options to maximize shareholder value. ObsEva retains worldwide, exclusive, commercial rights for nolasiban, except for the People’s Republic of China.”

Under the terms of the agreement with XOMA, ObsEva has sold and assigned all its rights to Ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions, to XOMA, including the Company’s license agreements with Organon and Merck KGaA, Darmstadt, Germany, and the intellectual property estate. In addition to the $15 million received in upfront proceeds, ObsEva is eligible to receive up to $98 million upon the achievement of certain development and regulatory milestones and sales milestones under the Company’s license agreement with Organon for Ebopiprant that was sold to XOMA in the transaction. In July 2021, ObsEva granted a license to Organon for the global development, manufacturing, and commercial rights to Ebopiprant. 

In conjunction with the closing of the transaction, ObsEva and JGB Management, Inc. (“JGB”) entered into a Consent and Amendment Agreement (the “Consent”), whereby JGB consented to ObsEva’s transaction with XOMA, and ObsEva agreed to maintain restricted cash equal to the total amount of outstanding principal under the outstanding convertible notes held by certain funds and accounts managed by JGB, subject to reduction upon conversion or payoff of the notes, and agreed to amend the maturity date for each note to December 31, 2023. Further information with respect to the Consent will be provided in a Form 6-K filed by ObsEva with the Securities and Exchange Commission on November 22, 2022.

As previously announced, ObsEva received a notification letter from Nasdaq advising the Company that it was not in compliance with Nasdaq Listing Rule 5450(b)(1)(A) requiring companies listed on the Nasdaq Global Select Market to maintain a minimum of $10 million in stockholders’ equity for continued listing. The sale proceeds are expected to improve the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the minimum stockholders’ equity requirement, and to position the Company to inform the Swiss court that it is no longer in an over-indebtedness position and to withdraw the pending Swiss moratorium proceedings.

Torreya acted as the exclusive financial advisor to ObsEva on the XOMA transaction.


About Nolasiban

Nolasiban is a novel, oral oxytocin receptor antagonist being developed for improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva retains worldwide, exclusive, commercial rights, except for the People’s Republic of China which has been sub-licensed to YuYuan BioScience (“Yuyuan”). Under the sublicense agreement with Yuyuan for nolasiban, ObsEva is entitled to receive aggregate milestone payments of up to $17 million upon the achievement of specified development, regulatory, and first sales milestones, and aggregate milestone payments of up to $115 million upon the achievement of additional, tiered sales milestones. In addition, Yuyuan has agreed to pay tiered royalties on net sales at percentages ranging from high-single digit to low-second digits.

Yuyuan’s IND application for a Phase 1 clinical trial of nolasiban was recently approved by the Center for Drug Evaluation at the Chinese National Medical Products Administration. Yuyuan plans to initiate a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical trial in China to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics of nolasiban in healthy adult female subjects in China.

About ObsEva

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a development program focused on improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might”, “ongoing”, “objective”, “plan”, “potential”, “predict”, “should”, “will”, “would”, or the negative of these and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include statements regarding the expected benefits of the XOMA transaction in providing future upside for shareholders, ObsEva’s cash runway and indebtedness position, the receipt of potential milestone payments under the agreement with XOMA, the receipt of potential milestone and royalty payments under the sublicense agreement with YuYuan, Yuyuan’s plans to initiate a Phase 1 clinical trial for nolasiban as designed, the timing, outcome and potential impact of the Company’s intended withdrawal of the pending moratorium proceedings before Swiss courts, and the Company’s plans for and ability to regain compliance with Nasdaq’s continued listing requirements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties in the ability of the proceeds from the sale to provide the expected benefits, ObsEva’s cash requirements and ability to resolve its current indebtedness position, the achievement of milestones under the agreement with XOMA, the achievement of milestones under the sublicense agreement with YuYuan, the ability of Yuyuan to conduct a Phase 1 clinical trial for nolasiban as designed, the outcome and potential impact of the Company’s intended withdrawal of the pending moratorium proceedings before Swiss courts, including with respect to ObsEva’s agreements with third parties and outstanding debt obligations, ObsEva’s ability to successfully restructure its operations, ObsEva’s ability to regain compliance with the continued listing rules of Nasdaq and the potential for Nasdaq to use its discretionary authority to delist the Company’s common shares in connection with the pending Swiss moratorium proceedings if ObsEva is not able to withdraw such proceedings, the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, ObsEva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed with the SEC on August 17, 2022 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:


CEO Administrative Contact

Shauna Dillon

shauna.dillon@obseva.ch

+41 22 552 1550


Investor Contact

Will Brown

will.brown@obseva.com

+1 (334) 313-2319






Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Benteler terminates the previously-announced sale to Tenaris of its Shreveport, Louisiana pipe manufacturing plant5.2.2023 19:20:07 CET | Press release

LUXEMBOURG, Feb. 05, 2023 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced today that Benteler North America Corporation has exercised its right to unilaterally terminate, effective immediately, the previously-announced agreement for the sale to Tenaris of 100% of the shares of U.S. steel pipe producer Benteler Steel & Tube Manufacturing Corporation. Tenaris is a leading global supplier of steel tubes and related services for the world’s energy industry and certain other industrial applications. Giovanni Sardagna Tenaris 1-888-300-5432 www.tenaris.com

SKEL fjárfestingafélag hf.: Amendment to the financial calendar and previously disclosed information4.2.2023 19:13:54 CET | Press release

The audit of SKEL’s financial statements for the year 2022, which has not been finalized, has resulted in a change of its presentation due to the company‘s transition into an investment company. Shares in subsidiaries were capitalized according to the equity method until year end 2021 but are recognised at fair value through profit or loss from the beginning of 2022. This results in a previously unrealized fair value change from 2021 of ISK 2.6 billion that was formerly accounted for directly through equity, will instead be recognised in the income statement for 2022. This change of presentation has no effect of previously announced equity for year-end 2022 of ISK 33.0-33.5 billion. Further, this does not alter the company’s ability to pay dividend. The company‘s estimated earnings net of tax will, however, increase by ISK 2.6 billion and amount to ISK 17.1-17.6 billion instead of ISK 14.5-15.0 billion as was previously announced on 31 January 2023. The company has decided to change th

City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing4.2.2023 05:18:05 CET | Press release

Vacaville high school students explore local career opportunities to honor National Career Technical Education Month VACAVILLE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- February is National Career Technical Education (CTE) Month, and the City of Vacaville joined the celebration by hosting a field trip for 58 Vacaville high school students February 3. The field trip included several locations around Vacaville and Solano County to explore advanced manufacturing and biotechnology. Every February, the Association for Career and Technical Education encourages communities to celebrate CTE Month, to raise awareness of the role that CTE has in readying learners for college and career success. This is also a time when the City of Vacaville recognizes and celebrates the contributions and achievements of community CTE partners including Solano Community College (SCC) and The Workforce Development Board of Solano County. “This field trip is an excellent opportunity for Vacaville’s young people to

Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®4.2.2023 00:30:00 CET | Press release

In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% at Week 52, as evaluated by the HS Clinical Response (HiSCR) measure1 Safety findings were consistent with the well-established safety profile of Cosentyx in its approved indications1 HS is a recurrent skin disease affecting one in 100 people worldwide, causing painful, boil-like abscesses that can lead to open wounds and irreversible scarring in the most intimate parts of the body2,3 There is only one approved therapy for HS and many patients, even those on treatment, still experience uncontrolled symptoms4 Basel, February 4, 2023 – Novartis announced today that The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx® (secukinumab) in moderate-to-severe hidradenitis suppurativa (HS)1. In two of the largest Phase III trials

Maha Energy meddelar reserv- och resursrapport per 31 december 20223.2.2023 21:45:00 CET | Pressemelding

McDaniel & Associates Consultants Ltd. (“McDaniel”) har genomfört sin första utvärdering av Maha Energy AB:s (publ) (”Maha” eller ”Bolaget”) reserver och resurser. Väsentliga förändringar från föregående års reserv- och resurssiffror är hänförliga till: att den tidigare annonserade utfarmningen och Joint Operating Agreement avtalet med Mafraq Energy LLC avseende Block 70 i Oman slutförs. Maha är operatör på Block 70 och Mahas licensandel minskar till 65 procent till följd härav.att den tidigare offentliggjorda transaktionen avseende den förväntade avyttringen av Mahas brasilianska verksamhet och följaktligen bolagets olje- och gastillgångar, där försäljningsavtalet undertecknades den 27 december 2022, resulterar i att inga reserver redovisas för fälten Tie och Tartaruga. Mahas reserver1 per 31 december 2022 2022 Maha Energy AB bruttoreserver före skatt (miljoner fat)KategoriTillgångar i USAMafraqTotalt1P1,340,421,762P2,740,523,263P3,590,624,21 De huvudsakliga förändringarna i årets res